Montreal, Quebec, October 23, 2019 – AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, announced today that Suzanne Campbell, Senior Brand Manager, Dermatology was inducted into the Canadian Healthcare Marketing Hall of Fame.

The Canadian Healthcare Marketing Hall of Fame awards were established to honor healthcare marketers who have contributed to the industry avocation and are an inspiration to others.

Suzanne Campbell credits her success to the team around her, which encompasses a motto that has governed her career—Together Everyone Achieves More (TEAM). “I constantly see that any idea or strategy gets so much better when you have the brain power of multiple colleagues and multiple perspectives,” said Campbell. “And that collaboration makes any project more robust.”

Suzanne was recognized for her work in hidradentis suppurativa (HS). HS is a painful, chronic, systemic, immune-mediated skin disease which affects between 1 to 3% of the global population however the diagnosis is often delayed or the condition is misdiagnosed with the true prevalence unknown.¹ HS is known to produce lesions in the skin that are inflamed (swollen), recurrent and chronic (lasting for an extended period of time). HS can have both a psychological and physical impact.

“When I started meeting people with HS, their patient journey, which had been a very negative one in the healthcare system, became my passion project.”

Stéphane Lassignardie, President, AbbVie Canada added: “We are very proud of Suzanne for this important acknowledgement. It is testament of our industry recognizing the importance of finding solutions for patients’ where there are no options and real medical need for solutions.”

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie

employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Media:

Eileen Murphy AbbVie Canada (514) 832-7788

eileen.murphy@abbvie.com

###

1 The Canadian Hidradenitis Suppurativa Foundation – www.hs-foundationcanada.org

Montreal, QC, September 25, 2019 – AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, announced today that Alberta, Manitoba, British Columbia and Saskatchewan are listing VENCLEXTA® (venetoclax) on their public formularies. VENCLEXTA monotherapy is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and for whom there are no other available treatment options. VENCLEXTA is an oral, once-daily medicine.

“People living with chronic lymphocytic leukemia in Western Canada finally have access to Venclexta, which is great news considering the nature of this disease. When faced with CLL, which can be recurrent, it is important to offer physicians and their patients highly effective options to tackle this illness,” explains Elizabeth Lye, Director of Research & Programs at Lymphoma Canada. “At Lymphoma Canada, we hope that soon all Canadians will have access to this treatment.”

VENCLEXTA is listed under the Alberta Health Services, Outpatient Cancer Drug Benefit Programⁱ, as a Part 3 benefit in Manitoba Pharmacare’s Home Oncology Drug Programⁱⁱ, by the British Columbia Cancer Lymphoma Tumour Groupⁱⁱⁱ and on the formulary of the Saskatchewan Cancer Agency^iv. All four provinces reimburse VENCLEXTA monotherapy for CLL patients who have received at least one prior therapy and who have failed a B-Cell receptor inhibitor (BCRi), with specific criteria.

For further information regarding specific provincial criteria consult the links below:

• Alberta Health Services, Outpatient Cancer Drug Benefit Program
• Manitoba Pharmacare, Drug Benefits and Interchangeability Formulary Amendments
• BC Cancer, Systemic Therapy Update
• Saskatchewan Cancer Agency Drug Formulary

“As a clinician, I need to have several treatment options available for my patients to effectively and successfully treat their CLL. It is great news that venetoclax is now reimbursed for Western Canadians,” says Dr. Carolyn Owen, MD, MDres(UK), FRCPC, Associate Professor, Division of Hematology and Hematological Malignancies, Foothills Medical Centre. “Venetoclax is an innovative molecule that selectively inhibits the BCL-2 protein, which is responsible for helping cancer cells survive in the blood.”

CLL, which is typically a slow-progressing cancer of the bone marrow and blood^v, is one of the most common types of leukemia in adults. In Canada, CLL accounts for approximately 1,745 newly diagnosed cases of leukemia each year and is responsible for more than 600 deaths a year.^vi

“When my physician told me I had CLL, I had no idea what this meant for my life expectancy. I am a husband, father and grandfather and I want to be around for my family as long as possible,” explains

Dale Jordan of Calgary, Alberta. “After discussing my options with my physician, he recommended VENCLEXTA. I am fortunate to live in a province where people can now access this medication.”

VENCLEXTA is being developed by AbbVie and Genentech, a member of the Roche Group. It is jointly commercialized by the companies in the U.S. and by AbbVie outside of the U.S.

About AbbVie Care

Canadians prescribed VENCLEXTA will have the opportunity to be enrolled in AbbVie Care, AbbVie’s signature care program. The program is designed to provide a wide range of customized services including reimbursement and financial support, pharmacy services, lab work reminders and coordination, personalized education and ongoing disease management support throughout the treatment. For more information, please visit www.abbviecare.ca.

About AbbVie

AbbVie is a global, research and development-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

-30-

Media Inquiries:

Muriel Haraoui muriel.haraoui@abbvie.com 514.717.3764

ⁱ Alberta Health Services. https://www.albertahealthservices.ca/assets/programs/ps-1025651-drug-benefit-list.pdf. Accessed September 2019.

ⁱⁱ Manitoba Pharmacare. Manitoba Drug Benefits and Interchangeability Formulary Amendments. Bulletin #105. Effective August 22, 2019. https://www.gov.mb.ca/health/mdbif/docs/bulletins/bulletin105.pdf. Accessed

September 2019.

ⁱⁱⁱ BC Cancer. Provincial Systemic Therapy Program. September 2019. http://www.bccancer.bc.ca/systemic- therapy-site/Documents/2019%20ST%20Updates/ST%20Update_Sep%202019.pdf. Accessed September 2019. ^iv Saskatchewan Cancer Agency Drug Formulary. September 3, 2019. http://www.saskcancer.ca/Drug%20Formulary%2009-2013. Accessed September 2019.

^v Lymphoma Canada. Chronic lymphocytic leukemia. Available at www.lymphoma.ca/lymphoma/lymphoma- 101/types-lymphoma/cll. Accessed September 2019.

^vi Canadian Cancer Statistics. Chronic lymphocytic leukemia statistics. www.cancer.ca/en/cancer- information/cancer-type/leukemia-chronic-lymphocytic-cll/statistics/?region=on. Accessed September 2019.

• INESSS recommends the reimbursement of VENCLEXTA^® (venetoclax) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia (CLL).ⁱ
• Adult patients with CLL taking VENCLEXTA in combination with rituximab can stop their therapy

Montreal, QC, June 25, 2019 –AbbVie (NYSE: ABBV), a global

biopharmaceutical company, today announced that the Institut national d’excellence en santé et en services sociaux (INESSS) recommends that the Minister include Venclexta, in combination with rituximab, on the Lists of Medications for the treatment of chronic lymphocytic leukemia (CLL), if the following conditions are met: exceptional medication and lessening of the economic burden.ⁱ VENCLEXTA in combination with rituximab is an effective treatment option that has the benefit of a finite treatment approach, meaning patients are able to stop their therapy after two years of treatment.

INESSS concludes that the evaluation of venetoclax’s efficacy and safety in combination with rituximab is

based on a good-quality study. The outcomes of that study demonstrated that venetoclax delays disease progression compared to intravenous chemotherapy. Although intravenous chemotherapy is not included on the Lists of Medications, INESSS has recognized its efficacy.ⁱ The most common adverse reactions with venetoclax in combination with rituximab were related to white blood cells. Furthermore, there is an unmet clinical need in CLL. The reimbursement of venetoclax in combination with rituximab would be beneficial in the care pathway of CLL patients. ⁱ

“The INESSS recommendation for VENCLEXTA plus rituximab is positive news for people living with CLL

in Quebec,” says Elizabeth Lye, Director of Research & Programs, Lymphoma Canada. “Receiving a diagnosis of CLL or any cancer is always shocking and overwhelming, therefore knowing that there are highly effective treatments available provides reassurance to people facing this uncertain journey.”

CLL, which is typically a slow-progressing cancer of the bone marrow and bloodⁱⁱ, is one of the most common types of leukemia in adults. In Canada, CLL accounts for approximately 2,465 newly diagnosed cases of leukemia each year and is responsible for more than 600 deaths a year.ⁱⁱⁱ The goal of treatment is to delay progression of the disease and improve quality of life.

VENCLEXTA continues to be investigated in CLL and other hematological diseases.

VENCLEXTA is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

Canadians prescribed VENCLEXTA will have the opportunity to be enrolled in AbbVie Care, AbbVie’s signature care program. The program is designed to provide a wide range of customized services including reimbursement and financial support, pharmacy services, lab work reminders and coordination, personalized education and ongoing disease management support throughout the treatment. For more information, please visit www.abbviecare.ca.

About AbbVie

AbbVie is a global, research and development-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

-30-

Media Inquiries:

Muriel Haraoui muriel.haraoui@abbvie.com 514.717.3764

i Institut national d’excellence en santé et en services sociaux (INESSS). Avis à la Ministre. www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Avis_au_ministre/Mai_2019/Venclexta_2019_05.pdf. Accessed June 2019.

ii Lymphoma Canada. Chronic lymphocytic leukemia. Available at www.lymphoma.ca/lymphoma/lymphoma-101/types- lymphoma/cll. Accessed June 2019.

iii Canadian Cancer Statistics. Chronic lymphocytic leukemia statistics. www.cancer.ca/en/cancer-information/cancer- type/leukemia-chronic-lymphocytic-cll/statistics/?region=on. Accessed June 2019.

^iv VENCLEXTA product monograph, AbbVie Corporation. Date of Preparation: September 27, 2016. Date of Revision: February 12, 2019. www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/VENCLEXTA_PM_EN.pdf. Accessed June 2019.

• MAVIRET is the first and only 8-week, pan-genotypic treatment for patients with chronic hepatitis C virus (HCV) infection without cirrhosis and who are new to ^*1
• MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease (CKD).

MONTREAL (Quebec), June 10, 2019 – AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company announced today that MAVIRET^TM (glecaprevir/pibrentasvir tablets) is now listed on the Nova Scotia Formulary and on the Manitoba Drug Benefits and Interchangeability Formulary, both effective since May 31, 2019. MAVIRET is a once-daily ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major HCV genotypes (GT1-6).² It is the only 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment.*

“In Nova Scotia, it is possible to reach the World Health Organization’s target of eliminating viral hepatitis as a major public threat by 2030. But in order to be successful, we need to implement strategies that include prevention, screening, timely and rapid testing, effective treatment and patient centred care for everyone living with hepatitis C,” says Dr. Lisa Barrett, MD, PhD, FRCPC, Assistant professor, Division of Infectious Diseases , Department of Medicine , Department of Microbiology & Immunology, Dalhousie University. “Today, with treatments including MAVIRET, we should be able to treat almost all people living with hepatitis C infection regardless of their background. This is very important for each individual person but also for elimination because treatment helps prevent the spread of HCV.”

MAVIRET is listed on the                                          for treatment-naive or treatment-experienced adult

patients with chronic hepatitis C genotype 1,2,3,4,5 or 6 infection.³

“At the Hepatitis Outreach Society of Nova Scotia (HepNS), we’ve worked over the last decade to

promote healthy living through information and support for people living with hepatitis C. But more

importantly, we’ve been committed to reducing the transmission rates. We are hopeful that with newer medications like MAVIRET being available in Nova Scotia and New Brunswick, our members will be able to seek the appropriate treatment and finally shed the stigma associated with this disease,” explains Alex MacDonnell, Acting Executive Director of HepNS.

MAVIRET is listed on the                                                                                                                                for treatment-naive

or treatment-experienced adult patients with chronic hepatitis C genotype 1,2,3,4,5 or 6 infection.⁴

“Hepatitis C is a serious health concern. When left untreated it leads to complications including liver cancer,” explains Dr. Kelly Kaita, Hepatologist, Director, Viral Hepatitis Investigative Unit at the

University of Manitoba. “Today, we have the knowledge and the expertise to test, diagnose and treat Canadians living with this deadly disease. Moreover, we have the right treatments, such as MAVIRET,

that can cure the disease in as little as eight weeks. Now is the time to act, especially as we are working

towards eradicating this virus by 2030.”

MAVIRET’s efficacy and safety were evaluated in nine phase II-III clinical trials, in over 2300 patients with genotype 1, 2, 3, 4, 5 or 6 HCV infection and with compensated liver disease (with or without cirrhosis).

About Hepatitis C

An estimated 250,000 people in Canada are living with chronic hepatitis C but as many as 44% are not aware that they have it.⁵ Left undiagnosed and untreated, chronic hepatitis C can lead to cirrhosis, liver cancer or liver failure. Currently, hepatitis C is the leading indication for liver transplant in Canada.⁶ AbbVie supports a range of efforts to help elevate and prioritize HCV elimination because we know achieving the shared goal of elimination by 2030 will take more than medicine. It will take transparent and collaborative partnerships with all stakeholders – industry, healthcare providers, healthcare systems, patient groups and their support networks. Joint efforts and maximizing the time we have left will enable us to reach this goal.

About MAVIRET

MAVIRET is approved in Canada for the treatment of chronic hepatitis C virus (HCV) in adults across all major genotypes (GT1-6).⁷ MAVIRET is a pan-genotypic, once-daily, ribavirin-free treatment that combines glecaprevir (100 mg), an NS3/4A protease inhibitor, and pibrentasvir (40 mg), an NS5A protein inhibitor. MAVIRET is taken once daily as three oral tablets.⁷

MAVIRET is an 8-week, pan-genotypic treatment that makes a virologic cure** possible in patients without cirrhosis who are new to treatment.*^,1 These patients represent the majority of people infected with HCV. MAVIRET is also approved in patients with specific treatment challenges, including those with compensated cirrhosis, who are carriers of one of the major genotypes, and those who previously had limited treatment options, such as patients with severe CKD, post-liver and post-renal transplant recipients*** and those patients with genotype 3 HCV infection.⁷ MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of CKD.⁷

Glecaprevir was discovered during the ongoing collaboration between AbbVie and

Enanta Pharmaceuticals (NASDAQ: ENTA) to develop HCV protease inhibitors and therapeutic regimens that include protease inhibitors.

* Patients without cirrhosis and new to treatment with direct-acting antivirals (DDAs), (i.e., either treatment-naive or did not respond to previous interferon-based treatments (pegylated interferon [peg IFN] +/- ribavirin or sofosbuvir–ribavirin +/-peg IFN).

** Patients who achieve a sustained virologic response at 12 weeks post treatment (SVR12) are considered cured of hepatitis C.

***MAVIRET is recommended for 12 weeks in liver or kidney transplant recipients who are HCV GT1-6 treatment-naive or HCV GT-1, -2, -4, -5 or -6 PRS (IFN or peg IFN, ribavirin and/or sofosbuvir)-treatment experienced. A 16-week treatment duration should be considered in transplant patients who are HCV GT-1 NS5A inhibitor experienced (but NS3/4A inhibitor-naive) or HCV GT-3 PRS- treatment experienced.

About AbbVie Care

Canadians prescribed MAVIRET will have the opportunity to be enrolled in AbbVie Care, AbbVie’s signature care program. The program is designed to provide a wide range of customized services including reimbursement and financial support, pharmacy services, personalized education and ongoing disease management support throughout the treatment.

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

###

Media:

Muriel Haraoui AbbVie Canada 514-717-3764

muriel.haraoui@abbvie.com

1 Decisions Resources Group. Hepatitis C virus: disease landscape & forecast 2016. January 2017.

2 CADTH Canadian Drug Expert Committee Recommendation – Final. www.cadth.ca/sites/default/files/cdr/complete/SR0523_Maviret_complete-Jan-25-18.pdf. Accessed June 2019. 3 Nova Scotia Pharmacare. Nova Scotia Formulary.

https://novascotia.ca/dhw/pharmacare/pharmacists_bulletins/Pharmacists_Bulletin_May_19-04.pdf. Accessed June 2019. 4 Manitoba Pharmacare Program. Manitoba Drug Benefits and Interchangeability Formulary. www.gov.mb.ca/health/mdbif/bulletin104.pdf. Accessed June 2019.

5 Canadian Network on Hepatitis C (CanHepC). Blueprint to inform hepatitis C elimination efforts in Canada. www.canhepc.ca/sites/default/files/media/documents/blueprint_hcv_2019_05.pdf. Accessed June 2019.

6 The Canadian Liver Foundation. www.liver.ca/how-you-help/advocate/. Accessed June 2019.

7 AbbVie Corporation MAVIRET (glecaprevir/pibrentasvir tablets) Product Monograph. Date of Preparation: August 16, 2017. Date of Revision: November 28, 2018. www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/MAVIRET_PM_EN.pdf . Accessed June 2019.

• pERC conditionally recommends reimbursement of VENCLEXTA^® (venetoclax) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.ⁱ
• Adult patients with CLL taking VENCLEXTA in combination with rituximab

Montreal, QC, June 6, 2019 –AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that the pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC) conditionally recommends reimbursement of VENCLEXTA® (venetoclax) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, irrespective of their 17p deletion status, only if the following condition is met: cost-effectiveness being improved to an acceptable level.ⁱ VENCLEXTA in combination with rituximab is an effective treatment option that has the benefit of a finite treatment approach, meaning patients can able to stop their therapy after two years of treatment.

“The pCODR recommendation for VENCLEXTA plus rituximab is positive news for Canadians living with

CLL,” says Elizabeth Lye, Director of Research & Programs, Lymphoma Canada. “Receiving a diagnosis of CLL or any cancer is always shocking and overwhelming, therefore knowing that there are highly effective treatments available provides reassurance to people facing this uncertain journey.”

CLL, which is typically a slow-progressing cancer of the bone marrow and bloodⁱⁱ, is one of the most

common types of leukemia in adults. In Canada, CLL accounts for approximately 2,465 newly diagnosed cases of leukemia each year and is responsible for more than 600 deaths a year.ⁱⁱⁱ The goal of treatment is to delay progression of the disease and improve quality of life.

“This is another tremendous milestone in our efforts to bring VENCLEXTA plus rituximab to Canadians living with CLL. This is a much needed treatment option as it is the first chemotherapy-free combination in CLL that allows patients a 24-month treatment duration,” says Stéphane Lassignardie, General Manager of Abbvie Canada.

VENCLEXTA is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

Canadians prescribed VENCLEXTA will have the opportunity to be enrolled in AbbVie Care, AbbVie’s signature care program. The program is designed to provide a wide range of customized services including reimbursement and financial support, pharmacy services, lab work reminders and coordination, personalized education and ongoing disease management support throughout the treatment and beyond. For more information, please visit www.abbviecare.ca.

About AbbVie

AbbVie is a global, research and development-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

-30-

Media Inquiries:

Muriel Haraoui muriel.haraoui@abbvie.com 514.717.3764

ii Lymphoma Canada. Chronic lymphocytic leukemia. Available at www.lymphoma.ca/lymphoma/lymphoma-101/types- lymphoma/cll. Accessed June 2019.

iii Canadian Cancer Statistics. Chronic lymphocytic leukemia statistics. www.cancer.ca/en/cancer-information/cancer- type/leukemia-chronic-lymphocytic-cll/statistics/?region=on. Accessed June 2019.

^iv VENCLEXTA product monograph, AbbVie Corporation. Date of Preparation: September 27, 2016. Date of Revision: February 12, 2019. www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/VENCLEXTA_PM_EN.pdf. Accessed June 2019.

• MAVIRET is the first and only 8-week, pan-genotypic treatment for patients with chronic hepatitis C virus (HCV) infection without cirrhosis and who are new to ^*1
• MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease (CKD).

MONTREAL (Quebec), May 30, 2019 – AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company announced today that MAVIRET^TM (glecaprevir/pibrentasvir tablets) is now listed on the New Brunswick Drug Plans Formulary. MAVIRET is a once-daily ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major HCV genotypes (GT1-6).² It is the only 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment.*

“Hepatitis C is the leading cause of liver failure and liver cancer in New Brunswick,” states Dr. Meaghan O’Brien, Hepatologist, Upper River Valley Hospital, Assistant professor, Division of General Internal Medicine, Department of Medicine, Dalhousie University. “With the introduction and subsequent approval and reimbursement of the new direct-acting antiviral therapies, such as MAVIRET, we have an opportunity to treat all Canadians living with this devastating and deadly disease. However, we need to ensure that the proper models of care are in place in order to reach our objectives both locally and across Canada.”

On the New Brunswick Drug Plans Formulary, MAVIRET is listed for treatment-naïve or treatment- experienced adult patients with chronic hepatitis C virus (HCV) including all genotypes 1-6. The listing became effective on May 16, 2019.³

“AbbVie believes that together, through innovative partnerships, we can make hepatitis C elimination the next public health success story. Along with healthcare professionals, governments and patient associations, together we can meet the WHO 2030 objective,” says Stéphane Lassignardie, General Manager, AbbVie Canada. “We are committed to further investigating and identifying opportunities to simplify the path to a cure.”

MAVIRET’s efficacy and safety were evaluated in nine phase II-III clinical trials, in over 2300 patients with genotype 1, 2, 3, 4, 5 or 6 HCV infection and with compensated liver disease (with or without cirrhosis).

An estimated 250,000 people in Canada are living with chronic hepatitis C but as many as 44% are not aware that they have it.⁴ Left undiagnosed and untreated, chronic hepatitis C can lead to cirrhosis, liver cancer or liver failure. Currently, hepatitis C is the leading indication for liver transplant in Canada.⁵ AbbVie supports a range of efforts to help elevate and prioritize HCV elimination because we know achieving the shared goal of elimination by 2030 will take more than medicine. It will take transparent and collaborative partnerships with all stakeholders – industry, healthcare providers, healthcare

systems, patient groups and their support networks. Joint efforts and maximizing the time we have left will enable us to reach this goal.

About MAVIRET

MAVIRET is approved in Canada for the treatment of chronic hepatitis C virus (HCV) in adults across all major genotypes (GT1-6).⁶ MAVIRET is a pan-genotypic, once-daily, ribavirin-free treatment that combines glecaprevir (100 mg), an NS3/4A protease inhibitor, and pibrentasvir (40 mg), an NS5A protein inhibitor. MAVIRET is taken once daily as three oral tablets.⁶

MAVIRET is an 8-week, pan-genotypic treatment that makes a virologic cure** possible in patients without cirrhosis who are new to treatment.*^,1 These patients represent the majority of people infected with HCV. MAVIRET is also approved in patients with specific treatment challenges, including those with compensated cirrhosis, who are carriers of one of the major genotypes, and those who previously had limited treatment options, such as patients with severe CKD, post-liver and post-renal transplant recipients*** and those patients with genotype 3 HCV infection.⁶ MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of CKD.⁶

Glecaprevir was discovered during the ongoing collaboration between AbbVie and

Enanta Pharmaceuticals (NASDAQ: ENTA) to develop HCV protease inhibitors and therapeutic regimens that include protease inhibitors.

* Patients without cirrhosis and new to treatment with direct-acting antivirals (DDAs), (i.e., either treatment-naive or did not respond to previous interferon-based treatments (pegylated interferon [peg IFN] +/- ribavirin or sofosbuvir–ribavirin +/-peg IFN).

** Patients who achieve a sustained virologic response at 12 weeks post treatment (SVR12) are considered cured of hepatitis C.

***MAVIRET is recommended for 12 weeks in liver or kidney transplant recipients who are HCV GT1-6 treatment-naive or HCV GT-1, -2, -4, -5 or -6 PRS (IFN or peg IFN, ribavirin and/or sofosbuvir)-treatment experienced. A 16-week treatment duration should be considered in transplant patients who are HCV GT-1 NS5A inhibitor experienced (but NS3/4A inhibitor-naive) or HCV GT-3 PRS- treatment experienced.

About AbbVie Care

Canadians prescribed MAVIRET will have the opportunity to be enrolled in AbbVie Care, AbbVie’s signature care program. The program is designed to provide a wide range of customized services including reimbursement and financial support, pharmacy services, personalized education and ongoing disease management support throughout the treatment.

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

###

Media:

Muriel Haraoui AbbVie Canada

514-717-3764

muriel.haraoui@abbvie.com

1 Decisions Resources Group. Hepatitis C virus: disease landscape & forecast 2016. January 2017.

2 CADTH Canadian Drug Expert Committee Recommendation – Final: www.cadth.ca/sites/default/files/cdr/complete/SR0523_Maviret_complete-Jan-25-18.pdf. Accessed May 2019. 3 New Brunswick Prescription Drug Program. www2.gnb.ca/content/dam/gnb/Departments/h- s/pdf/en/NBDrugPlan/FormularyUpdates/NBDrugPlansBulletin999.pdf. Accessed May 2019.

4 Canadian Network on Hepatitis C (CanHepC). Blueprint to inform hepatitis C elimination efforts in Canada. www.canhepc.ca/sites/default/files/media/documents/blueprint_hcv_2019_05.pdf. Accessed May 2019.

5 The Canadian Liver Foundation. www.liver.ca/how-you-help/advocate/. Accessed May 2019.

6 AbbVie Corporation MAVIRET (glecaprevir/pibrentasvir tablets) Product Monograph. Date of Preparation: August 16, 2017. Date of Revision: November 28, 2018. www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/MAVIRET_PM_EN.p . Accessed May 2019.

• Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance (pCPA), Ontario is the first province to reimburse
• VENCLEXTA is the first and only BCL-2 inhibitor to be approved in
• A need exists for CLL patients who have failed novel oral ⁱ

Montreal, QC, May 23, 2019 – AbbVie (NYSE: ABBV), a global, research and development-driven biopharmaceutical company, announced today that Ontario is the first province to reimburse VENCLEXTA® (venetoclax) monotherapy under its Drugs and Devices Division’s (DDD) Exceptional Access Program effective May 13, 2019.ⁱⁱ VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have no other treatment options. VENCLEXTA is an oral, once-daily medicine.

This listing follows the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance (pCPA) earlier this year.

“People living with chronic lymphocytic leukemia in Ontario finally have access to VENCLEXTA, which is great news considering the nature of this disease. When faced with CLL, which can be recurrent, it is important to offer physicians and their patients highly effective options to tackle this illness,” explains Elizabeth Lye, Director of Research & Programs at Lymphoma Canada. “At Lymphoma Canada, we hope that soon all Canadians will have access to this treatment.”

VENCLEXTA monotherapy will be available through the Exceptional Access Program for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have failed treatment with at least one prior therapy (including B-cell receptor inhibitors) or who have experienced intolerance to ibrutinib.

“When I meet a patient for the first time, I always explain that CLL is a type of blood cancer that is chronic and that some may relapse after being in remission. In fact, most of the patients I see in my clinic have often already gone through another line of treatment. Therefore, I want to ensure I have the appropriate treatments available for my patients in a timely manner,” says Dr. Peter Anglin, MD, FRCPC,

MBA, Hematologist and Physician Lead, Stronach Regional Cancer Centre. “I am thrilled that Ontario is

the first province to reimburse venetoclax; it’s a positive step for people living with CLL who need access to this much needed treatment.”

CLL, which is typically a slow-progressing cancer of the bone marrow and bloodⁱⁱⁱ, is one of the most common types of leukemia in adults. In Canada, CLL accounts for approximately 2,465 newly diagnosed cases of leukemia each year and is responsible for more than 600 deaths a year.^iv

“It’s been a long time coming for wonderful news like this. I can remember reading about clinical trials for this treatment several years ago and thinking how promising it sounded for people like me who have already been treated with more than one line of therapy and relapsed,” states Mark Silverstein of

Aurora, Ontario. “Now it’s finally here! Another treatment option in the CLL world has been approved and reimbursed in the province of Ontario, and hopefully soon coming to every Canadian province. And thank you AbbVie for your commitment to bringing VENCLEXTA to those who need it.”

VENCLEXTA received a Notice of Compliance with Conditions (NOC/c) from Health Canada on September 30, 2016. The therapy was approved as monotherapy for previously treated CLL patients, who have either a genetic mutation known as 17p deletion, or who do not have the mutation but have no other available treatment options, and who have received at least one other therapy. The 17p deletion is a genetic mutation that is found in 3 to 10 percent of people with previously untreated CLL and up to 50 percent of relapsed or refractory cases.^v Under Health Canada’s NOC/c policy, AbbVie will provide Health Canada with data from additional studies to assess the clinical benefit of VENCLEXTA in these patient populations.^vi

“This agreement with the pCPA and subsequently the listing in Ontario are positive steps towards patients living with CLL accessing a medication that serves an unmet medical need,” stated Stéphane Lassignardie, General Manager of AbbVie Canada. “AbbVie is committed to changing the way blood cancers are treated with innovative new treatment options.”

VENCLEXTA continues to be investigated in CLL and other hematological diseases.

VENCLEXTA is being developed by AbbVie and Genentech, a member of the Roche Group. It is jointly commercialized by the companies in the U.S. and by AbbVie outside of the U.S.

Canadians prescribed VENCLEXTA will have the opportunity to be enrolled in AbbVie Care, AbbVie’s signature care program. The program is designed to provide a wide range of customized services including reimbursement and financial support, pharmacy services, lab work reminders and coordination, personalized education and ongoing disease management support throughout the treatment and beyond.

About AbbVie

AbbVie is a global, research and development-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

-30-

Media Inquiries:

Muriel Haraoui muriel.haraoui@abbvie.com 514.717.3764

iJain P. et al. Long-Term Outcomes for Patients With Chronic Lymphocytic Leukemia Who Discontinue Ibrutinib. Cancer. 2017 Jun 15;123(12):2268-2273.

ii Ontario Ministry of Health and Long-Term Care. http://health.gov.on.ca/en/pro/programs/drugs/eap_mn.aspx. Accessed May 2019.

iii Lymphoma Canada. Chronic lymphocytic leukemia. Available at http://www.lymphoma.ca/lymphoma/lymphoma-101/types- lymphoma/cll. Accessed May 2019.

iv Canadian Cancer Statistics. Chronic lymphocytic leukemia statistics. http://www.cancer.ca/en/cancer-information/cancer- type/leukemia-chronic-lymphocytic-cll/statistics/?region=on. Accessed May 2019.

v Schnaiter A. et al. 17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach. Hematol Oncol Clin N Am. 2013;27:289–301.

vi VENCLEXTA product monograph, AbbVie Corporation. Date of Preparation: September 27, 2016. Date of Revision: February 12, 2019. http://www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/VENCLEXTA_PM_EN.pdf. Accessed May 2019.